ERBB2 and neoplasm: These compounds deliver highly toxic anticancer agents (ACAs) to and selectively eliminate tumor cells27, as demonstrated by an anti-HER2 ADC that was effective against target cells, even when patients had therapeutic resistance against anti-HER2 antibodies28.